Why the study?
Does the cessation of ACEi/ARB improve eGFR without worsening cardiovascular outcomes in patients with advanced CKD?
Does the cessation of ACEi/ARB improve eGFR without worsening cardiovascular outcomes in patients with advanced CKD?
There is currently a lack of definitive evidence regarding the cardiovascular and renal impacts of stopping versus continuing ACEi/ARB therapy in advanced non-dialysis CKD.
No takes yet. Share an insight, caveat, or question.
Evidence insufficient to prefer ACEi/ARBs in advanced non-dialysis CKD; leaves open CV effects of cessation.
Ahmed et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: